Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Terminated Phase 1 Trials for Tanespimycin (DB05134)

IndicationStatusPhase
DBCOND0028534 (Adult Acute Minimally Differentiated Myeloid Leukemia (M0))Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT0010327217-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic CancerTreatment